SCHEMBL16213611

SCHEMBL16213611

CCOC(=O)CCCc1cc2c(-c3ccnc(C)c3)nn(C(c3ccccc3)(c3ccccc3)c3ccccc3)c2cc1[N+](=O)[O-]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ADORA2A P29274 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
TNF P01375 1/20 0.33
FAAH O00519 2/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
MAPK1 P28482 3/20 0.33
CTSD P07339 1/20 0.33
CTSB P07858 1/20 0.33
KMT2A Q03164 1/20 0.33
ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16213543 0.95 ADORA2A (0.35) ALDH1A1TDP1ADORA2AMAPTCYP4F2
SCHEMBL19567956 0.84 MAPK1 (0.35) ALDH1A1SMN1; SMN2KDM4EMAPTMAPK1
SCHEMBL20920127 0.82 L3MBTL1 (0.38) ALDH1A1SMN1; SMN2KDM4EMAPTMAPK1
SCHEMBL16213206 0.82 MAPK1 (0.34) ALDH1A1MAPTMAPK1CTSBKMT2A
SCHEMBL16213443 0.81 CTSB (0.43) ALDH1A1KDM4EMAPTMAPK1CTSB
SCHEMBL17567304 0.80 LMNA (0.37) ALDH1A1TDP1CYP3A4CYP2C9CYP2C19
SCHEMBL16213478 0.79 L3MBTL1 (0.38) ALDH1A1SMN1; SMN2ADORA2AKDM4EMAPT
SCHEMBL16213082 0.78 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2KDM4EMAPTMAPK1
SCHEMBL17555399 0.78 MAPT (0.42) ALDH1A1TDP1SMN1; SMN2MAPTKMT2A
SCHEMBL17555398 0.78 MAPT (0.42) ALDH1A1TDP1SMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759805-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2020-09-01 US disclosed
EP-2991654-B1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2018-11-21 EP disclosed
US-20180319804-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-11-08 US disclosed
US-10065967-B2 Compounds that are ERK inhibitors Merck, Sharp & Dohme Corp. (US) 2018-09-04 US disclosed
US-20170320882-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-9745307-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-29 US disclosed
US-20160068532-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-03-10 US disclosed
EP-2991654-A2 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-03-09 EP disclosed
WO-2014179154-A2 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759805-B2 Compounds that are ERK inhibitors MAPK1, MAPK4, MAP3K1 ALDH1A1 450/4885TDP1 3066/4885CYP1A2 1895/4885
US-20180319804-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 ALDH1A1 560/4885TDP1 2886/4885CYP1A2 2344/4885
US-20170320882-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 ALDH1A1 560/4885TDP1 2886/4885CYP1A2 2344/4885
US-10065967-B2 Compounds that are ERK inhibitors MAPK1, MAPK4, MAP3K1 ALDH1A1 450/4885TDP1 3066/4885CYP1A2 1895/4885
US-20160068532-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAP3K20, MAPK6 ALDH1A1 809/4885TDP1 3234/4885CYP1A2 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.